People with lupus are at an increased risk of depression. Lupus is a chronic condition with recurring symptoms that can ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

SOUTH SAN FRANCISCO, Calif. - Alumis Inc. (NASDAQ: ALMS), currently valued at $388 million and trading near its 52-week low of $6.29, and ACELYRIN, INC. (NASDAQ: SLRN) have entered into a definitive ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

Adicet Bio (ACET) announced the FDA has granted fast track designation to ADI-001 for the potential treatment of adult patients with refractory ...

Among the research grants, Taimalieutu Kiwi Tamasese from The Family Centre has been awarded $80,000 in funding to lead a study on gout within Pasifika communities living in the Wellington and ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...